首页MLLCF • OTCMKTS
add
Molecular Partners AG
市场资讯
财务信息
损益表
收入
净收入
| (CHF) | 2025年3月info | 年同比变化 |
|---|---|---|
收入 | — | — |
经营支出 | 1614.20万 | 259.35% |
净收入 | -1677.10万 | -48.09% |
净利润率 | — | — |
每股收益 | -0.45 | — |
息税折旧摊销前利润 | -1559.00万 | -2.21% |
有效税率 | 0.01% | — |
资产负债表
总资产
负债总额
| (CHF) | 2025年3月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 1.31亿 | -24.82% |
总资产 | 1.41亿 | -23.98% |
负债总额 | 1290.40万 | -24.36% |
权益总额 | 1.28亿 | — |
发行在外的股份 | 3726.89万 | — |
市净率 | 1.23 | — |
资产回报率 | -26.94% | — |
资本回报率 | -29.41% | — |
现金流
现金净变动
| (CHF) | 2025年3月info | 年同比变化 |
|---|---|---|
净收入 | -1677.10万 | -48.09% |
来自运营的现金 | -1708.00万 | -0.18% |
投资现金 | 3496.30万 | 98.53% |
融资现金 | -30.20万 | -0.67% |
现金净变动 | 1749.70万 | 1,588.90% |
自由现金流 | -1371.92万 | -22.38% |
简介
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
成立时间
2004
员工数量
159
